Sagimet Biosciences Inc.SGMT
What Sagimet Biosciences Inc. does.
We are a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Our lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Our second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne.
The critical role of FASN overactivity in MASH makes it an attractive target for drug therapy. Our FASN inhibitor, denifanstat, targets multiple drivers of MASH by reducing steatosis, inflammation and fibrosis.
MASH is an aggressive form of metabolic dysfunction-associated steatotic liver disease (MASLD), a condition where an abnormal buildup of excess fat, known as steatosis, occurs in the liver unrelated to the consumption of alcohol. According to a study published in 2023, MASH is a growing epidemic that affected more than 265 million people worldwide in 2019. It is often associated with insulin resistance, type 2 diabetes, cardiovascular disease, and an increase in overall mortality. Left untreated, damage to the liver can lead to cirrhosis or liver cancer, potentially making liver transplantation necessary. There are few approved treatments for non-cirrhotic MASH (stages F1, F2 and F3 fibrosis) and no approved treatments for cirrhotic MASH (F4). We believe FASN inhibition may offer a meaningful therapeutic solution for this unmet need. The therapeutic potential of our FASN inhibitor, denifanstat, stems from its differentiated mechanism of action directly targeting the three key drivers of MASH pathogenesis: steatosis, inflammation, and fibrosis.
Revenue and profit, by fiscal year.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | $2.0M | — | — |
| Net income | — | -$30.5M | -$27.9M | -$45.6M | -$51.0M |
More on SGMT.
- Sagimet Biosciences Inc. summary
- Sagimet Biosciences Inc. financial statements
- Sagimet Biosciences Inc. key metrics
- Sagimet Biosciences Inc. health scores and style box
- Sagimet Biosciences Inc. earnings
- Sagimet Biosciences Inc. dividends
- Sagimet Biosciences Inc. valuation
- Sagimet Biosciences Inc. ownership and insiders
- Sagimet Biosciences Inc. peers
Figures from Sagimet Biosciences Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.